troglitazone

DRUG2 trials

Sponsors

Dana-Farber Cancer Institute, Parke-Davis

Conditions

AtherosclerosisDiabetes MellitusSarcoma

Phase 2

Troglitazone in Treating Patients With Liposarcoma

CompletedNCT00003058

Dana-Farber Cancer InstituteSarcoma

Start: 1997-06-30End: 2000-01-31Updated: 2017-02-13

TART - Troglitazone Atherosclerosis Regression Trial

CompletedNCT00116545

Parke-DavisAtherosclerosis, Diabetes Mellitus

Start: 1997-01-31End: 2000-04-30Target: 288Updated: 2009-12-11